BORIANI, Giuseppe
 Distribuzione geografica
Continente #
NA - Nord America 73.469
EU - Europa 22.723
AS - Asia 10.892
OC - Oceania 310
SA - Sud America 152
AF - Africa 63
Continente sconosciuto - Info sul continente non disponibili 47
Totale 107.656
Nazione #
US - Stati Uniti d'America 72.823
GB - Regno Unito 8.390
IT - Italia 4.546
CN - Cina 3.628
SG - Singapore 2.810
SE - Svezia 2.607
DE - Germania 2.581
HK - Hong Kong 1.925
TR - Turchia 1.822
UA - Ucraina 1.732
BG - Bulgaria 854
FI - Finlandia 500
FR - Francia 453
BZ - Belize 400
AU - Australia 299
ID - Indonesia 215
IE - Irlanda 203
RU - Federazione Russa 187
CA - Canada 169
NL - Olanda 114
IN - India 109
PL - Polonia 107
ES - Italia 97
JP - Giappone 84
LT - Lituania 71
BE - Belgio 59
MX - Messico 56
MY - Malesia 53
BR - Brasile 40
VN - Vietnam 40
EU - Europa 36
RO - Romania 36
CH - Svizzera 34
CO - Colombia 30
CL - Cile 29
IR - Iran 28
GR - Grecia 25
GE - Georgia 24
IL - Israele 24
ZA - Sudafrica 23
CZ - Repubblica Ceca 22
TW - Taiwan 22
AR - Argentina 19
PT - Portogallo 17
PH - Filippine 15
RS - Serbia 15
TH - Thailandia 15
KR - Corea 14
AT - Austria 13
EG - Egitto 13
CU - Cuba 11
DK - Danimarca 11
HU - Ungheria 11
NZ - Nuova Zelanda 11
PE - Perù 11
PK - Pakistan 11
A2 - ???statistics.table.value.countryCode.A2??? 9
NO - Norvegia 8
EC - Ecuador 7
IQ - Iraq 7
VE - Venezuela 7
KZ - Kazakistan 6
MD - Moldavia 6
SK - Slovacchia (Repubblica Slovacca) 6
BD - Bangladesh 5
GH - Ghana 5
SA - Arabia Saudita 5
SI - Slovenia 5
BO - Bolivia 4
CR - Costa Rica 4
DO - Repubblica Dominicana 4
KE - Kenya 4
UG - Uganda 4
AE - Emirati Arabi Uniti 3
AL - Albania 3
BT - Bhutan 3
JO - Giordania 3
LK - Sri Lanka 3
MK - Macedonia 3
NG - Nigeria 3
NP - Nepal 3
PS - Palestinian Territory 3
UY - Uruguay 3
AZ - Azerbaigian 2
BA - Bosnia-Erzegovina 2
DZ - Algeria 2
EE - Estonia 2
LA - Repubblica Popolare Democratica del Laos 2
LU - Lussemburgo 2
MA - Marocco 2
PY - Paraguay 2
TN - Tunisia 2
TZ - Tanzania 2
UZ - Uzbekistan 2
AP - ???statistics.table.value.countryCode.AP??? 1
BJ - Benin 1
CY - Cipro 1
ET - Etiopia 1
GL - Groenlandia 1
HR - Croazia 1
Totale 107.648
Città #
Fairfield 12.851
Woodbridge 7.524
Southend 7.258
Houston 5.829
Ashburn 5.744
Seattle 4.936
Cambridge 4.149
Chandler 4.145
Wilmington 4.073
Jacksonville 3.635
Ann Arbor 2.815
Dearborn 2.335
Singapore 2.246
Hong Kong 1.877
Nyköping 1.463
Modena 1.419
Beijing 1.308
San Diego 1.244
Izmir 1.214
New York 1.105
Princeton 893
Sofia 850
San Jose 847
Eugene 729
Belize City 400
London 397
Helsinki 329
Dallas 325
Milan 286
Falls Church 256
Boardman 216
Jakarta 204
Rome 201
Bologna 192
Fremont 187
Chicago 184
Dublin 180
Saint Louis 169
Perth 168
Shanghai 165
Norwalk 163
Las Vegas 139
Albuquerque 133
Hefei 128
Redwood City 120
Kunming 114
Atlanta 111
Nanjing 109
Kilburn 100
Columbus 94
Munich 87
Guangzhou 83
Grafing 75
Santa Clara 70
Toronto 67
Jinan 65
Chiswick 61
Florence 58
Naples 58
Sydney 55
Lappeenranta 54
Prescot 51
Hounslow 48
Nanchang 47
Turin 46
Saint Petersburg 45
Brussels 43
Sergii 43
Wuhan 39
Fuzhou 38
Parma 38
Des Moines 36
Philadelphia 36
San Giuliano Milanese 35
Tokyo 33
Bremen 31
Los Angeles 30
Shenyang 30
Acton 29
Amsterdam 29
Central 29
San Francisco 29
Islington 28
Ottawa 28
Esslingen am Neckar 27
Milwaukee 27
Verona 27
Frankfurt am Main 26
Reggio Emilia 25
Wandsworth 25
Dong Ket 24
Forlimpopoli 24
Zhengzhou 24
Mountain View 22
Paris 22
Forlì 21
Warsaw 21
Chongqing 20
Perugia 20
Shenzhen 20
Totale 87.508
Nome #
Long-Term Implications of Atrial Fibrillation in Patients With Degenerative Mitral Regurgitation 552
Corrigendum to: 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC (Eur Heart J (2021) 42 (373–498) DOI: 10.1093/eurheartj/ehaa612) 377
La sindrome da pacemaker. 346
Atrial Fibrillation in the Setting of Acute Pneumonia: Not a Secondary Arrhythmia 320
Linee guida AIAC all'impianto di pacemaker, dispositivi per la resincronizzazione cardiaca, defibrillatori automatici e loop recorder. Update 2011. 310
Registro Italiano Pacemaker e Defibrillatori: Bollettino Periodico 2016 Associazione Italiana di Aritmologia e Cardiostimolazione 292
Screening for atrial fibrillation: A Report of the AF-SCREEN International Collaboration 268
The future of continuing medical education: the roles of medical professional societies and the health care industry: Position paper prepared with contributions from the European Society of Cardiology Committees for Advocacy, Education and Industry Relations, Endorsed by the Board of the European Society of Cardiology 264
Prevalence and clinical significance of left bundle branch block according to classical or strict definition criteria in permanent pacemaker patients 256
Rationale and design of the Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation (ARTESiA) trial 254
2018 EHRA expert consensus statement on lead extraction: Recommendations on definitions, endpoints, research trial design, and data collection requirements for clinical scientific studies and registries: Endorsed by APHRS/HRS/LAHRS 245
Guía de práctica clínica de la ESC 2013 sobre estimulación cardiaca y terapia de resincronización cardiaca 240
Clinically guided pacemaker choice and setting: pacemaker expert programming study 231
2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: The Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA) 217
Acute hemodynamic effects of intravenous adenosine in patients with associated pulmonary arterial hypertension: Comparison with intravenous epoprostenol 217
Implantable cardioverter-defibrillator–computed respiratory disturbance index accurately identifies severe sleep apnea: The DASAP-HF study 216
The 2018 European Heart Rhythm Association Practical Guide on the use of non-Vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: Executive summary 213
108th ENMC International Workshop, 3rd Workshop of the MYO-CLUSTER project: EUROMEN, 7th International Emery-Dreifuss Muscular Dystrophy (EDMD) Workshop, 13-15 September 2002, Naarden, The Netherlands. 212
Antithrombotic Therapy for Atrial Fibrillation: CHEST Guideline and Expert Panel Report 212
Role of the tricuspid regurgitation after mitraclip and transcatheter aortic valve implantation: a systematic review and meta-analysis 210
Adverse outcomes in patients with atrial fibrillation and peripheral arterial disease: a report from the EURObservational research programme pilot survey on atrial fibrillation 208
'Real-world' management and outcomes of patients with paroxysmal vs. non-paroxysmal atrial fibrillation in Europe: The EURObservational Research Programme-Atrial Fibrillation (EORP-AF) General Pilot Registry 206
Atrial fibrillation in patients with active malignancy and use of anticoagulants: Under-prescription but no adverse impact on all-cause mortality 206
P wave dispersion and short-term vs. late atrial fibrillation recurrences after cardioversion 204
Home care for heart failure: can caregiver education prevent hospital admissions? A randomized trial in primary care 202
Letter by Gasparini and Boriani Regarding Article, "Cardiac Resynchronization Therapy in Patients With Permanent Atrial Fibrillation: Results From the Resynchronization for Ambulatory Heart Failure Trial (RAFT)" 200
QRS interval time-related changes and prognosis in heart failure 199
Detection of new atrial fibrillation in patients with cardiac implanted electronic devices and factors associated with transition to higher device-detected atrial fibrillation burden 197
2015 HRS/EHRA/APHRS/SOLAECE expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing 196
Atrioventricular junction ablation in patients with atrial fibrillation treated with cardiac resynchronization therapy: positive impact on ventricular arrhythmias, implantable cardioverter-defibrillator therapies and hospitalizations 194
Prediction of cardiac resynchronization therapy response: value of calibrated integrated backscatter imaging. 191
Cardiac device therapy in patients with left ventricular dysfunction and heart failure: ‘real-world’ data on long-term outcomes (mortality, hospitalizations, days alive and out of hospital) 191
The increased risk of stroke/transient ischemic attack in women with a cardiac implantable electronic device is not associated with a higher atrial fibrillation burden 191
QRS pattern and improvement in right and left ventricular function after cardiac resynchronization therapy: a radionuclide study 189
Health economics and the European Heart Rhythm Association. 188
Emery-Dreifuss Muscular Dystrophy-Associated Mutant Forms of Lamin A Recruit the Stress Responsive Protein Ankrd2 into the Nucleus, Affecting the Cellular Response to Oxidative Stress 188
Cause of death and predictors of all-cause mortality in anticoagulated patients with nonvalvular atrial fibrillation: Data from ROCKET AF 188
Cardiac involvement in systemic sclerosis: identification of high-risk patient profiles in different patterns of clinical presentation 187
Remote Monitoring of Patients with an Implanted Device and Patients' Outcomes: The Potential for "Win-Win" Dynamics. 187
12-year Temporal Trend in Referral Pattern and Test Results of Stress Echocardiography in a Tertiary Care Referral Center with Moderate Volume Activities and Cath-lab Facility 187
'Real-world' atrial fibrillation management in Europe: observations from the 2-year follow-up of the EURObservational Research Programme-Atrial Fibrillation General Registry Pilot Phase 186
Electrocardiogram Alterations Associated With Psychotropic Drug Use and CACNA1C Gene Variants in Three Independent Samples 186
Risk stratification of cardiovascular and heart failure hospitalizations using integrated device diagnostics in patients with a cardiac resynchronization therapy defibrillator 186
Rate vs. rhythm control and adverse outcomes among European patients with atrial fibrillation 185
EACVI/EHRA Expert Consensus Document on the role of multi-modality imaging for the evaluation of patients with atrial fibrillation 185
Cardiac resynchronization therapy: is systole all that matters? 183
Comprehensive risk reduction in patients with atrial fibrillation: emerging diagnostic and therapeutic options--a report from the 3rd Atrial Fibrillation Competence NETwork/European Heart Rhythm Association consensus conference. 182
The MOnitoring Resynchronization dEvices and CARdiac patiEnts (MORE-CARE) Randomized Controlled Trial: Phase 1 Results on Dynamics of Early Intervention With Remote Monitoring 181
Validation of a simple risk stratification tool for patients implanted with Cardiac Resynchronization Therapy: The VALID-CRT risk score 181
Randomized comparison between Ramp and Burst+ atrial antitachycardia pacing therapies in patients suffering from sinus node disease and atrial fibrillation and implanted with a DDDRP device. 181
Beta-blocker treatment guided by head-up tilt test in neurally mediated syncope 181
Elevated TGF β2 serum levels in Emery-Dreifuss Muscular Dystrophy: Implications for myocyte and tenocyte differentiation and fibrogenic processes 181
The wearable cardioverter-defibrillator: Current technology and evolving indications 181
Decrease in patient radiation exposure by a tantalum filter during electrophysiological procedures. 180
Inappropriate shock for myopotential over-sensing in a patient with subcutaneous ICD 180
Cardiac resynchronization therapy in the real world: need to focus on implant rates, patient selection, co-morbidities, type of devices, and complications 180
Management of Phrenic Stimulation in CRT Patients over the Long Term: Still an Unmet Need ? 179
Asymptomatic lone atrial fibrillation - how can we detect the arrhythmia? 179
Implantable dual-chamber defibrillator for the selective treatment of spontaneous atrial and ventricular arrhythmias: arrhythmia incidence and device performance. 179
2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy 179
Regional differences in presentation and treatment of patients with atrial fibrillation in Europe: A report from the EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry 179
Cardiolaminopathies from bench to bedside: challenges in clinical decision-making with focus on arrhythmia-related outcomes 179
Cardiac resynchronization therapy in the real world: need to upgrade outcome research 179
New classification of geometric patterns considering left ventricular volume in patients with chronic aortic valve regurgitation: Prevalence and association with adverse cardiovascular outcomes 179
2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy 178
Health care cost analysis of enhanced pacing modalities in bradycardia patients: Portuguese case study on the results of the MINERVA trial 178
A randomized double-blind comparison of biventricular versus left ventricular stimulation for cardiac resynchronization therapy: the Biventricular versus Left Univentricular Pacing with ICD Back-up in Heart Failure Patients (B-LEFT HF) trial. 178
Extending survival by reducing sudden death with implantable cardioverter-defibrillators: a challenging clinical issue in non-ischaemic and ischaemic cardiomyopathies 178
The QRS interval in patients treated with resynchronization therapy: which value? 177
Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: Executive summary 177
Cost Effectiveness of Treatments for Stroke Prevention in Atrial Fibrillation: Focus on the Novel Oral Anticoagulants 177
Lifetime cost-effectiveness of prophylactic implantation of a cardioverter defibrillator in patients with reduced left ventricular systolic function: Results of markov modelling in a european population 176
'Pill-in-the-pocket' treatment for recent-onset atrial fibrillation [4] 176
Rhythm discrimination by rate branch and QRS morphology in dual chamber implantable cardioverter defibrillators 175
Presence and duration of atrial fibrillation detected by continuous monitoring: crucial implications for the risk of thromboembolic events. 175
Reducing unnecessary right ventricular pacing with the managed ventricular pacing mode in patients with sinus node disease and AV block. 175
Heart failure after myocardial revascularization: Risk markers 174
Far-field R wave oversensing in dual-chamber pacemakers designed for atrial arrhythmia management: effect of pacing site and lead tip to ring distance 174
Effect of high-pass filtering on ECG signal on the analysis of patients prone to atrial fibrillation 174
Occupational radiation exposure in the electrophysiology laboratory with a focus on personnel with reproductive potential and during pregnancy: A European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS) 174
Ventricular fibrillation during sleep in an adolescent with hypertrophic cardiomyopathy: the difficulty of risk stratification and the power of the cardioverter-defibrillator 174
Targeting the arrhythmogenic substrate in atrial fibrillation: focus on structural remodeling 173
Prognostic implications of the Doppler restrictive filling pattern in hypertrophic cardiomyopathy 173
Cardiac resynchronization therapy: effects on left and right ventricular ejection fraction during exercise. 173
Cardiac tachyarrhythmias and patient values and preferences for their management: The European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE) 173
Role of ventricular Autocapture function in increasing longevity of DDDR pacemakers: a prospective study. 173
Cardiac resynchronization therapy and electrical storm: results of the OBSERVational registry on long-term outcome of ICD patients (OBSERVO-ICD) 173
Protective role of statins in COVID 19 patients: importance of pharmacokinetic characteristics rather than intensity of action 173
Combined use of morphology discrimination, sudden onset, and stability as discriminating algorithms in single chamber cardioverter defibrillators 172
Oral loading of propafenone: restoring its role before restoring rhythm 172
Implant rates of cardiac implantable electrical devices in Europe: A systematic literature review 172
Overweight and obesity in patients with atrial fibrillation: Sex differences in 1-year outcomes in the EORP-AF General Pilot Registry 172
Can we predict new AF occurrence in single-chamber ICD patients? Insights from an observational investigation 172
P-wave characteristics after electrical external cardioversion: Predictive indexes of relapse 172
Cardiac resynchronization by pacing: an electrical treatment of heart failure 171
The empowerment of translational research: lessons from laminopathies 171
Switching among Equivalents in Chronic Cardiovascular Therapies: 'Real World' Data from Italy 171
Edoxaban in Atrial Fibrillation and Venous Thromboembolism—Ten Key Questions and Answers: A Practical Guide 171
P-wave Variability and Atrial Fibrillation 171
The Italian subcutaneous implantable cardioverter-defibrillator survey: S-ICD, why not? 171
Totale 19.961
Categoria #
all - tutte 511.743
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 511.743


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202021.701 0 0 0 0 2.837 4.693 5.403 2.518 3.021 1.172 1.531 526
2020/202122.437 1.993 841 2.000 2.486 2.603 1.348 2.848 2.882 1.051 2.005 1.309 1.071
2021/202215.465 664 1.848 1.677 712 427 1.286 887 786 1.655 1.369 2.411 1.743
2022/202311.536 1.660 974 714 826 1.469 1.536 259 1.187 1.758 206 597 350
2023/20249.853 393 632 435 803 2.283 1.440 447 1.696 223 253 327 921
2024/20254.137 1.151 386 730 1.788 82 0 0 0 0 0 0 0
Totale 110.715